JP2000513352A - リポソームインフルエンザワクチンの組成物および方法 - Google Patents
リポソームインフルエンザワクチンの組成物および方法Info
- Publication number
- JP2000513352A JP2000513352A JP10502632A JP50263298A JP2000513352A JP 2000513352 A JP2000513352 A JP 2000513352A JP 10502632 A JP10502632 A JP 10502632A JP 50263298 A JP50263298 A JP 50263298A JP 2000513352 A JP2000513352 A JP 2000513352A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- liposome
- cytokine
- effective
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/829—Liposomes, e.g. encapsulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.インフルエンザウイルスに対する哺乳動物被験体の免疫化に使用するための リポソームワクチン組成物であって、 リポソームの懸濁物であって、その中にカプセル化された、 該被験体において免疫応答を刺激するのに有効なインフルエンザサブユニット 抗原、および 該免疫応答を増強するのに有効な少なくとも1つの免疫刺激サイトカインを有 する、懸濁物、 を含有する、組成物。 2.前記抗原および前記サイトカインが、前記組成物中で同じリポソームに同時 カプセル化されている、請求項1に記載の組成物。 3.前記抗原および前記サイトカインが、前記組成物中で異なるリポソーム集団 にカプセル化されている、請求項1に記載の組成物。 4.前記インフルエンザサブユニット抗原が、インフルエンザウイルスのHA(赤 血球凝集素)およびNA(ノイラミニダーゼ)ウイルス表面タンパク質、またはそ れらの抗原性変異体を含む、請求項1に記載の組成物。 5.前記サイトカインが、IL-1、IL-2、IL-4、IL-6、IL-7、IL-12、IL-15、IFN- γ、およびGM-CSFからなる群から選択される、請求項1に記載の組成物。 6.前記サイトカインがインターロイキン-2(IL-2)である、請求項5に記載の 組成物。 7.前記サイトカインが、顆粒球マクロファージコロニー刺激因子(GM-CSF)で ある、請求項5に記載の組成物。 8.前記サイトカインが、IL-2およびGM-CSFの組合せである、請求項5に記載の 組成物。 9.前記リポソームが、少なくとも70モルパーセントのジミリストイル(dimyri stoyl)ホスファチジルコリン(DMPC)を含む、請求項1に記載の組成物。 10.前記リポソームが、約0.25μ〜5.0μの平均直径を有する大きな多層状小 胞である、腹腔内、筋肉内、または皮下投与に使用するための、請求項1に記載 の組成物。 11.前記リポソームが、約30〜80nmの平均直径を有する小さな単層小胞である 、静脈内投与、鼻腔内投与、または筋肉内投与に使用するための、請求項1に記 載の組成物。 12.前記リポソームが、750と10,000ダルトンとの間の分子量を有するポリエ チレングリコール(PEG)鎖で誘導体化された極性の頭部基を有する1〜25モル パーセントの脂質を含む、請求項11に記載の組成物。 13.前記組成物が、投与後6ヶ月までに前記被験体において100%の抗体陽転 を産生するのに有効である、請求項1に記載の組成物。 14.前記組成物が、投与後9ヶ月までに前記被験体において100%の抗体陽転 を産生するのに有効である、請求項13に記載の組成物。 15.インフルエンザウイルスに対する哺乳動物被験体の免疫化に使用するため のリポソームワクチン組成物であって、 該被験体において免疫応答を刺激するのに有効なインフルエンザサブユニット 抗原、および 該免疫応答を増強するのに有効な少なくとも1つの免疫刺激サイトカイン を含む組成物であり、ここで、該抗原および該サイトカインの少なくとも一方が リポソーム懸濁物内でカプセル化され、そして該組成物は、投与後6ヶ月までに 該被験体において100%の抗原陽転を産生するのに有効である、組成物。 16.前記組成物が、投与後9ヶ月までに前記被験体において100%の抗体陽転 を産生するのに有効である、請求項15に記載の組成物。 17.インフルエンザウイルスによる哺乳動物被験体の感染を防止する方法であ って、該方法は、 リポソーム懸濁物であって、その中にカプセル化された、 被験体において免疫応答を刺激するのに有効なインフルエンザサブユニット抗 原、および 該免疫応答を増強するのに有効な少なくとも1つの免疫刺激サイトカインを有 する、リポソーム懸濁物を含有するリポソームワクチン組成物の有効量を該被験 体に投与する工程を含む、方法。 18.前記リポソームが、約30〜80nmの平均直径を有する小さな単層小胞である 、静脈内、鼻腔内、または筋肉内投与に使用するための、請求項17に記載の方 法。 19.前記リポソームが、750と10,000ダルトンとの間の分子量を有するポリエ チレングリコール(PEG)鎖で誘導体化された極性の頭部基を有する1〜25モル パーセントの脂質を含む、静脈内、鼻腔内、または筋肉内投与に使用するための 、請求項18に記載の方法。 20.インフルエンザウイルスによる哺乳動物被験体の感染を防止方法であって 、該方法は、 該被験体において免疫応答を刺激するのに有効なインフルエンザサブユニット 抗原、および 該免疫応答を増強するのに有効な少なくとも1つの免疫刺激サイトカイン を含有するリポソームワクチン組成物の有効量を該被験体に投与する工程を含み 、ここで、該抗原および該サイトカインの少なくとも一方がリポソームの懸濁物 中にカプセル化され、そして該組成物は、投与後6ヶ月までに該被験体において 100%の抗原陽転を産生するのに有効である、方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2006396P | 1996-06-24 | 1996-06-24 | |
US60/020,063 | 1996-06-24 | ||
PCT/IL1997/000210 WO1997049423A2 (en) | 1996-06-24 | 1997-06-24 | Liposomal influenza vaccine composition and method |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008149959A Division JP2008260779A (ja) | 1996-06-24 | 2008-06-06 | リポソームインフルエンザワクチンの組成物および方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2000513352A true JP2000513352A (ja) | 2000-10-10 |
JP2000513352A5 JP2000513352A5 (ja) | 2005-02-10 |
JP4227195B2 JP4227195B2 (ja) | 2009-02-18 |
Family
ID=21796541
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50263298A Expired - Fee Related JP4227195B2 (ja) | 1996-06-24 | 1997-06-24 | リポソームインフルエンザワクチンの組成物および方法 |
JP2008149959A Withdrawn JP2008260779A (ja) | 1996-06-24 | 2008-06-06 | リポソームインフルエンザワクチンの組成物および方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008149959A Withdrawn JP2008260779A (ja) | 1996-06-24 | 2008-06-06 | リポソームインフルエンザワクチンの組成物および方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US5919480A (ja) |
EP (1) | EP0954286B1 (ja) |
JP (2) | JP4227195B2 (ja) |
AT (1) | ATE422352T1 (ja) |
AU (1) | AU731705B2 (ja) |
CA (1) | CA2258878C (ja) |
DE (1) | DE69739253D1 (ja) |
WO (1) | WO1997049423A2 (ja) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7731972B1 (en) * | 2000-02-04 | 2010-06-08 | Vlaams Interuniversitair Instituut Voor Biotechnologie | Immunoprotective influenza antigen and its use in vaccination |
AU1208499A (en) * | 1997-10-31 | 1999-05-24 | Cistron Biotechnology, Inc. | Encapsulated immunomodulators useful as vaccine adjuvants |
AT407958B (de) | 1999-02-11 | 2001-07-25 | Immuno Ag | Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation |
ATE317267T1 (de) * | 2000-11-07 | 2006-02-15 | Immunovaccine Technologies Inc | Impfstoffe mit erhöhter immunantwort und verfahren zur deren herstellung |
AU3652602A (en) * | 2000-11-15 | 2002-05-27 | Us Gov Health & Human Serv | Sol-fusin: use of gp64-6his to catalyze membrane fusion |
TWI228420B (en) * | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
IL159334A0 (en) * | 2001-06-25 | 2004-06-01 | Yissum Res Dev Co | A method for preparation of vesicles loaded with biological material and different uses thereof |
EP1401492B1 (en) * | 2001-07-05 | 2009-05-20 | LTB4 Sweden AB | Ltb4 as vaccine adjuvant |
EP1528915A2 (en) * | 2002-07-03 | 2005-05-11 | Aphton Corporation | Liposomal vaccine |
US20040247661A1 (en) * | 2002-07-03 | 2004-12-09 | Dov Michaeli | Liposomal vaccine |
US20050169979A1 (en) * | 2002-07-03 | 2005-08-04 | Dov Michaeli | Liposomal vaccine |
EP1617808A4 (en) | 2003-04-25 | 2011-11-02 | Penn State Res Found | METHOD AND SYSTEM FOR THE SYSTEMIC DISTRIBUTION OF GROWTH-INHIBITORS OF LIPID-DERIVED BIOACTIVE COMPOUNDS |
EP1628636A1 (de) * | 2003-05-09 | 2006-03-01 | Novosom AG | Injizierbare liposomale depots zum wirkstoffdelivery |
KR101280094B1 (ko) * | 2003-08-11 | 2013-06-28 | 사이단호진한다이비세이부쯔뵤우겐큐우카이 | 점막 면역을 유도할 수 있는 보강제를 함유한 신규한 백신 |
ES2342606T3 (es) * | 2003-08-21 | 2010-07-09 | Lipotek Pty Ltd. | Blanco in vivo de celulas dentriticas. |
FR2868951B1 (fr) * | 2004-04-15 | 2006-07-21 | Ethypharm Sa | Compositions contenant ds vesicules lamellaires incorporant un principe actif peu soluble dans l'eau et produits intermediaires utiles pour leur preparation |
US20050260260A1 (en) * | 2004-05-19 | 2005-11-24 | Edward Kisak | Liposome compositions for the delivery of macromolecules |
US20060177468A1 (en) * | 2005-01-05 | 2006-08-10 | Philadelphia Health and Education Corporation (d/b/a Drexel University College of Medicine | Delivery vehicles, bioactive substances and viral vaccines |
CA2523032A1 (en) | 2005-10-07 | 2007-04-07 | Immunovaccine Technologies Inc. | Vaccines for cancer therapy |
EP2197497B1 (en) | 2007-09-27 | 2016-06-01 | ImmunoVaccine Technologies Inc. | Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo |
US20100209452A1 (en) * | 2007-10-03 | 2010-08-19 | Immunovaccine Technologies, Inc | Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof |
WO2009090650A2 (en) * | 2008-01-16 | 2009-07-23 | Ben-Gurion University Of The Negev Research And Development Authority | Vaccine for alzheimer's disease |
CN102056622B (zh) * | 2008-06-05 | 2016-04-06 | 免疫疫苗技术有限公司 | 包含脂质体、抗原、多核苷酸和含疏水物质的连续相的载体的组合物 |
US8877242B2 (en) * | 2008-07-14 | 2014-11-04 | Polypid Ltd. | Sustained-release drug carrier composition |
EP2391370B1 (en) | 2009-02-02 | 2015-06-03 | Galmed Research and Development Ltd. | Methods and compositions for treating alzheimer's disease |
US9907746B2 (en) | 2009-07-06 | 2018-03-06 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
CA2767392C (en) | 2009-07-06 | 2017-03-14 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
AU2010272167B2 (en) | 2009-07-14 | 2016-11-17 | Polypid Ltd. | Sustained-release drug carrier composition |
WO2011044158A1 (en) * | 2009-10-09 | 2011-04-14 | New York Blood Center, Inc. | Immunopotentiator-linked oligomeric influenza immunogenic compositions |
WO2011089595A2 (en) | 2010-01-19 | 2011-07-28 | Polypid Ltd. | Sustained-release nucleic acid matrix compositions |
CA2840079C (en) * | 2010-07-06 | 2018-07-03 | Variation Biotechnologies Inc. | Compositions and methods for treating influenza |
US20130323280A1 (en) | 2011-01-13 | 2013-12-05 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
MX359103B (es) | 2011-01-13 | 2018-09-14 | Variation Biotechnologies Inc | Composiciones y sus usos en el tratamiento de infecciones virales. |
BR112014007927B1 (pt) | 2011-10-06 | 2021-04-13 | Immunovaccine Technologies Inc | Composições de lipossoma compreendendo um adjuvante e usos das referidas composições e usos das referidas composições |
US20140328876A1 (en) | 2011-11-18 | 2014-11-06 | Variation Biotechnologies Inc. | Synthetic derivatives of mpl and uses thereof |
WO2013104995A2 (en) | 2012-01-12 | 2013-07-18 | Variation Biotechnologies, Inc. | Compositions and methods for treating viral infections |
WO2013111012A2 (en) | 2012-01-27 | 2013-08-01 | Variation Biotechnologies, Inc. | Methods and compositions for therapeutic agents |
CN103736090B (zh) * | 2014-01-27 | 2016-03-02 | 中国医学科学院医学生物学研究所 | 甲磺酸去铁胺佐剂及含甲磺酸去铁胺佐剂的疫苗 |
CN110151702A (zh) * | 2019-06-24 | 2019-08-23 | 昆明医科大学 | 聚乙二醇修饰流感疫苗脂质体及其制备方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4117113A (en) * | 1974-06-25 | 1978-09-26 | National Research Development Corporation | Immunological preparations |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4235877A (en) * | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4426330A (en) | 1981-07-20 | 1984-01-17 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
US4534899A (en) | 1981-07-20 | 1985-08-13 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
JPH0720857B2 (ja) * | 1988-08-11 | 1995-03-08 | テルモ株式会社 | リポソームおよびその製法 |
JPH04500203A (ja) * | 1988-08-25 | 1992-01-16 | ザ リポソーム カンパニー,インコーポレイテッド | インフルエンザワクチンおよび新規なアジュバント |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
JP3037994B2 (ja) * | 1989-11-02 | 2000-05-08 | テルモ株式会社 | リポソーム表面への蛋白質吸着抑制剤 |
JP3220180B2 (ja) * | 1991-05-23 | 2001-10-22 | 三菱化学株式会社 | 薬剤含有タンパク質結合リポソーム |
WO1994001133A1 (en) * | 1992-07-08 | 1994-01-20 | Schering Corporation | Use of gm-csf as a vaccine adjuvant |
US6326353B1 (en) * | 1993-03-23 | 2001-12-04 | Sequus Pharmaceuticals, Inc. | Enhanced circulation effector composition and method |
JPH09501169A (ja) * | 1993-08-06 | 1997-02-04 | オパーバス ホールディング ビー ヴィ | 小胞に生体高分子物質を高度に充填する方法 |
AUPM500494A0 (en) * | 1994-04-12 | 1994-05-05 | Minister For Agriculture & Rural Affairs For The State Of New South Wales, The | Composition for use in increasing mucosal immunity |
-
1997
- 1997-06-23 US US08/880,238 patent/US5919480A/en not_active Expired - Lifetime
- 1997-06-24 AT AT97927355T patent/ATE422352T1/de not_active IP Right Cessation
- 1997-06-24 WO PCT/IL1997/000210 patent/WO1997049423A2/en active Application Filing
- 1997-06-24 JP JP50263298A patent/JP4227195B2/ja not_active Expired - Fee Related
- 1997-06-24 AU AU31882/97A patent/AU731705B2/en not_active Ceased
- 1997-06-24 EP EP97927355A patent/EP0954286B1/en not_active Expired - Lifetime
- 1997-06-24 DE DE69739253T patent/DE69739253D1/de not_active Expired - Lifetime
- 1997-06-24 CA CA002258878A patent/CA2258878C/en not_active Expired - Fee Related
-
2008
- 2008-06-06 JP JP2008149959A patent/JP2008260779A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JP2008260779A (ja) | 2008-10-30 |
AU731705B2 (en) | 2001-04-05 |
CA2258878C (en) | 2008-03-18 |
EP0954286A2 (en) | 1999-11-10 |
ATE422352T1 (de) | 2009-02-15 |
WO1997049423A3 (en) | 1998-02-19 |
US5919480A (en) | 1999-07-06 |
DE69739253D1 (de) | 2009-03-26 |
EP0954286B1 (en) | 2009-02-11 |
AU3188297A (en) | 1998-01-14 |
CA2258878A1 (en) | 1997-12-31 |
JP4227195B2 (ja) | 2009-02-18 |
WO1997049423A2 (en) | 1997-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4227195B2 (ja) | リポソームインフルエンザワクチンの組成物および方法 | |
CA2212382C (en) | Cochleate delivery vehicles | |
US6015576A (en) | Method for inducing a systemic immune response to an antigen | |
AU689505B2 (en) | Protein- or peptide-cochleate vaccines and methods of immunizing using the same | |
AU4221489A (en) | Affinity associated vaccine | |
JP2005525992A (ja) | 生物学的物質を充填した小胞の調製法およびそれらの様々な使用 | |
JP2997073B2 (ja) | 鼻腔内または吸入投与用ワクチン製剤およびその製造方法 | |
US6117449A (en) | Method for inducing a systemic immune response to a hepatitis antigen | |
LT5435B (lt) | Vakcinos kompozicijos mišinys su alkilfosfatidilcholinu | |
US20100047329A1 (en) | Novel Vaccination Carrier | |
WO1997030725A1 (en) | Cochleat delivery vehicles | |
BR112012033284B1 (pt) | veículo vacinal para induzir resposta imune celular, e, composição vacinal | |
US20070026005A1 (en) | Vaccine composition comprising il-12 adjuvant encapsulated in controlled-release microsphere | |
US20230181711A1 (en) | Immunogenic composition comprising an antigenic moiety and a liposomal formulation, method of producing the composition, the composition for use as a medicament, in particular for use as a vaccine | |
WO2003000232A2 (en) | Method for preparation of vesicles loaded with immunostimulator y oligodeoxynucleotides | |
Gould-Fogerite et al. | Cochleate delivery vehicles: applications in vaccine delivery | |
US20020136762A1 (en) | Method for inducing a systemic immune response to an antigen | |
Hampl et al. | Effects of phospholipid composition on adjuvant efficiency of liposomes | |
Onuigbo et al. | Evaluation of immunomodulatory effect of immunace on adjuvanticity of 1, 2-dioleoyl-3-trimethylammoniumpropane-based liposomes | |
Homhuan et al. | Characterization and protection in mice of outer membrane proteins from Pasteurella multocida A: 1 incorporated in lipid vaccine delivery systems | |
AAand1Attama | African Jour Res | |
McGhee¹ et al. | OVERVIEW OF THE COMMON MUCOSAL IMMUNE SYSTEM AND ORAL VACCINES | |
Hussain | Formulation and the characterisation of cationic liposomal adjuvants for the delivery of a promising subunit tuberculosis vaccine | |
Wijburg et al. | Liposomes as Systemic and Mucosal Delivery Vehicles | |
JP2004161781A (ja) | 経口ワクチン |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040618 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040618 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070710 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070925 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071105 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071109 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071217 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071206 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080311 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080606 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20081030 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20081120 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20081128 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111205 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111205 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121205 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |